The research collaboration team of Kristy Ainslie and Eric M. Bachelder focuses on the development of new vaccines and immunotherapies, including nanoparticle delivery systems for STING agonists and the application of STING agonists in seasonal influenza vaccines and autoimmune diseases. This evidence concerns the gene STING1 and influenza.